{"result": "(\"entity\"<|>FQ<|>ORGANIZATION<|>FQ refers to Fibrosis Cystic, a genetic disorder affecting the lungs and digestive system, leading to chronic inflammation and other complications.)\n##\n(\"entity\"<|>EPOC<|>ORGANIZATION<|>EPOC stands for Chronic Obstructive Pulmonary Disease, a progressive lung disease that causes breathing difficulties and is often associated with chronic inflammation.)\n##\n(\"entity\"<|>IPE<|>ORGANIZATION<|>IPE refers to patients with exocrine pancreatic insufficiency, a condition often seen in patients with cystic fibrosis that affects nutrient absorption.)\n##\n(\"entity\"<|>VITAMIN A<|>EVENT<|>Vitamin A supplementation is recommended for patients with cystic fibrosis to maintain adequate serum levels and support overall health.)\n##\n(\"entity\"<|>VITAMIN D<|>EVENT<|>Vitamin D supplementation is suggested for patients with cystic fibrosis, especially those with low sun exposure, to ensure proper bone health.)\n##\n(\"entity\"<|>VITAMIN E<|>EVENT<|>Vitamin E is recommended for all patients with cystic fibrosis to help manage oxidative stress and support immune function.)\n##\n(\"entity\"<|>VITAMIN K<|>EVENT<|>Vitamin K supplementation is indicated for patients with cystic fibrosis who have specific conditions affecting absorption or prolonged antibiotic use.)\n##\n(\"entity\"<|>VITAMIN B12<|>EVENT<|>Vitamin B12 supplementation is necessary for patients with cystic fibrosis who have undergone ileal resection to prevent deficiency.)\n##\n(\"entity\"<|>DEXA<|>EVENT<|>DEXA is a bone density test recommended for all cystic fibrosis patients starting at age 8-10 to monitor bone health and osteoporosis risk.)\n##\n(\"relationship\"<|>FQ<|>EPOC<|>FQ and EPOC are both chronic diseases that involve inflammation and can lead to complications such as osteoporosis in patients<|>7)\n##\n(\"relationship\"<|>FQ<|>IPE<|>Patients with FQ often experience exocrine pancreatic insufficiency, which affects their nutritional status and requires specific dietary management<|>8)\n##\n(\"relationship\"<|>VITAMIN A<|>FQ<|>Vitamin A supplementation is recommended for patients with FQ to help manage their condition and maintain health<|>6)\n##\n(\"relationship\"<|>VITAMIN D<|>FQ<|>Vitamin D supplementation is suggested for patients with FQ to support bone health and counteract deficiencies<|>6)\n##\n(\"relationship\"<|>VITAMIN E<|>FQ<|>Vitamin E is recommended for patients with FQ to help manage oxidative stress associated with the disease<|>6)\n##\n(\"relationship\"<|>VITAMIN K<|>FQ<|>Vitamin K supplementation is indicated for patients with FQ who have conditions affecting absorption, highlighting the nutritional challenges they face<|>6)\n##\n(\"relationship\"<|>VITAMIN B12<|>FQ<|>Vitamin B12 supplementation is necessary for patients with FQ who have undergone ileal resection, indicating the need for tailored nutritional support<|>6)\n##\n(\"relationship\"<|>DEXA<|>FQ<|>DEXA scans are recommended for patients with FQ to monitor bone density and assess osteoporosis risk, reflecting the disease's impact on bone health<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: En la FQ es frecuente encontrar niveles anormales de ácidos grasos esenciales en suero, plasma y en las membranas de células sanguíneas y en biopsias de tejidos, por lo que puede ser útil su medición, si está disponible en los centros. Los hallazgos más frecuentes (respecto a las personas sanas) son el descenso en los niveles de ácido linoleico y de docosahexaenoico (DHA). Estas alteraciones podrían estar implicadas en la fisiopatología de la enfermedad, ya que son más pronunciadas en los pacientes con fenotipos más graves65, 66.\n\nTanto la EPOC como las BQ o la FQ son enfermedades con un trasfondo de inflamación crónica sistémi-\n---\nTema 35. Soporte nutricional en el paciente con patología pulmonar, enfermedad pulmonar... 565\n\nTabla 6. Suplementación de vitaminas en fibrosis quística.\n\n| Vitamina | Pacientes candidatos | Dosis inicial | Control |\n|----------|----------------------|---------------|---------|\n| A | IPE | Retinol 4000-10000 UI/día Carotenos 1 mg/kg/día (máximo 50 mg/día) 12 semanas y luego mantener con máximo de 10 mg/día | Niveles séricos (retinol) |\n| D | IPE y en baja exposición solar | 400-1000 UI/día < 1 año 800-2000 UI/día Niños 1-10 años 800-4000 UI/día >10 años | Niveles séricos (25-OH-D) |\n| E | Todos los pacientes (alfa tocoferol) | 50 UI/día < 1 año 100-400 UI /día resto | Niveles séricos (alfa-tocoferol) corregidos por colesterol > 5,4 mg/g |\n| K | IPE no controlada, hepatopatía, resección colónica, antibioterapia prolongada. | 0,3 a 1,0 mg/día < 1 año 1 mg día a 10 mg/día resto (mejor diariamente). | Clínica**, tiempo de protrombina**, PIVKA-II***, osteocalcina infracarboxilada***. |\n| B12 | Resección ileal. | 100 μg IM/mes | Niveles séricos. |\n| Otras | Según ingesta*. | | |\n\nFactores de conversión: UI a mg:\nVitamina A: UI x 0,3 = μg;\nVitamina D: UI / 40 = μg;\nVitamina E: acetato de all-rac-alfa-tocoferol: UI = mg;\nVitamina E: RRR-alfa-tocoferol: UI / 1,49 = mg.\nIPE: pacientes con insuficiencia pancreática exocrina.\n* El resto de vitaminas no son necesarias si la ingesta del paciente es normal.\n** Marcadores muy poco sensibles en cuanto al déficit.\n*** «Proteína inducida por la ausencia de vitamina K» o la «osteocalcina infra-carboxilada», son marcadores mucho más sensibles pero más caros.\nModificada de Turck D et al.52.\n\nca, por lo que se propone medir además la proteína C reactiva67. Otros autores han empleado otros marcadores de inflamación como el TNF-alfa, la IL-6, de oxidación37, 46, 47; no obstante, para la práctica clínica su utilidad es limitada.\n\n4.4. Evaluación del estado óseo\n\nLos consensos recomiendan realizar DEXA a todos los pacientes con FQ a partir de los 8-10 años de edad, y repetirlo de forma individualizada (con una frecuencia entre 1 y 5 años) en función de la edad, el valor previo de la densitometría, si se ha instaurado tratamiento y de los factores de riesgo para desarrollar osteoporosis. En menores de 20 años se recomienda realizar densidad mineral ósea total en columna lumbar y, en mayores de esta edad, columna lumbar y cadera. Se debe valorar el Z-Score en niños, mujeres premenopáusicas y varones menores de 50 años (se considera «baja densidad mineral ósea relacionada con la FQ» por debajo de –2 SDS). En mujeres postmenopáusicas y en varones mayores de 50 años se debe emplear el T-Score (se considera osteoporosis si < de –2,5 SDS). En sujetos menores de 20 años en los que la talla sea menor de una desviación estándar respecto a los de sujetos sanos de similar edad y sexo, se recomienda que el Z-Score se ajuste por la talla (o edad para la talla) para evitar sobreestimación de déficits en la densidad mineral ósea27, 52, 68.\n\nEn pacientes con EPOC, la prevalencia de osteoporosis y de fracturas es muy elevada. Los datos de prevalencia varían de 5 a 60%, dependiendo de los mét\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}